ReviewBMC surgery2024
Impact of tumor size on the outcomes of hepatic resection for hepatocellular carcinoma: a retrospective study.
Review in BMC surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Risk of Long-Term Survival After Hepatic Resection for Hepatocellular and Intrahepatic Cholangiocarcinoma: Population-Based Analysis in Korea.Journal of Korean medical science · 2026Article
- Benefits and risks of simultaneous versus staged laparoscopic resection for colorectal cancer with synchronous liver metastases.Surgery today · 2026Article
- Impact of patient factors on outcomes in robotic major and minor hepatectomy: importance of patient selection.Journal of robotic surgery · 2026Article
- Multicenter Validation of a RAR-Based Nomogram for Predicting Postoperative Progression in HBV-Related Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- High Expression of Follistatin is a Risk Factor Predicting Poor Overall Survival in Hepatocellular Carcinoma Patients.Journal of hepatocellular carcinoma · 2026Article
- Treatment Outcomes in Patients Receiving Carbon-Ion Radiotherapy Versus Hepatectomy for Hepatocellular Carcinoma (≥4 cm): A Retrospective Study in Japan.Journal of clinical medicine · 2025Article
- Machine learning analysis of survival outcomes in breast cancer patients treated with chemotherapy, hormone therapy, surgery, and radiotherapy.Scientific reports · 2025Article
- Development and validation of a small-sample machine learning model to predict 5-year overall survival in patients with hepatocellular carcinoma.BMC cancer · 2025Article
- Determinants of Survival and Prognostic Factors in Patients Undergoing Liver Resection for Primary Hepatic Carcinoma-A Follow-Up Study.Clinics and practice · 2025Article
- A non-invasive nomogram for the prediction of poor prognosis of hepatocellular carcinoma based on the novel marker Interleukin-41.BMC cancer · 2025Article
- A deep learning-based clinical-radiomics model predicting the treatment response of immune checkpoint inhibitors (ICIs)-based conversion therapy in potentially convertible hepatocelluar carcinoma patients: a tumor marker prognostic study.International journal of surgery (London, England) · 2025Article
- Seizing tumor factors for mortality and survival outcomes following liver resection in Indonesia's hepatocellular carcinoma patients.Annals of hepato-biliary-pancreatic surgery · 2025Article
- Early Recurrence of Hepatocellular Carcinoma in Patients without Microscopic Vascular Invasion: Clinicopathological Characteristics and Risk Factors.Journal of hepatocellular carcinoma · 2025Article
- Performance of AI-based machine learning models for overall survival prediction in advanced hepatocellular carcinoma patients receiving immunoradiotherapy.Frontiers in pharmacology · 2025Article
- From CNNs to SAM: A Survey of Deep Learning Techniques for Liver Tumor Segmentation in CT Images.IEEE access : practical innovations, open solutions · 2025Article
- Machine Learning Prognostic Model for Post-Radical Resection Hepatocellular Carcinoma in Hepatitis B Patients.Journal of hepatocellular carcinoma · 2025Article
- Key prognostic factors in transarterial chemoembolization combined with sorafenib treatment for hepatocellular carcinoma with portal vein tumor thrombosis.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the impact of tumor size on the perioperative and long-term outcomes of liver resection for hepatocellular carcinoma (HCC).
methodsWe reviewed the patients' data who underwent liver resection for HCC between November 2009 and 2019. Patients were divided into 3 groups according to the tumor size. Group I: HCC < 5 cm, Group II: HCC between 5 to 10 cm, and Group III: HCC ≥ 10 cm in size.
resultsThree hundred fifteen patients were included in the current study. Lower platelets count was noted Groups I and II. Higher serum alpha-feto protein was noted in Group III. Higher incidence of multiple tumors, macroscopic portal vein invasion, nearby organ invasion and presence of porta-hepatis lymph nodes were found in Group III. More major liver resections were performed in Group III. Longer operation time, more blood loss and more transfusion requirements were found in Group III. Longer hospital stay and more postoperative morbidities were noted in Group III, especially posthepatectomy liver failure, and respiratory complications. The median follow-up duration was 17 months (7-110 months). Mortality occurred in 100 patients (31.7%) and recurrence occurred in 147 patients (46.7%). There were no significant differences between the groups regarding recurrence free survival (Log Rank, p = 0.089) but not for overall survival (Log Rank, p = 0.001).
conclusionHCC size is not a contraindication for liver resection. With proper selection, safe techniques and standardized care, adequate outcomes could be achieved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.